Cellectis
CLLS
40 hedge funds and large institutions have $18.3M invested in Cellectis in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 16 closing their positions.
3.45% less ownership
Funds ownership: 22.65% → 19.2% (-3.4%)
20% less funds holding
Funds holding: 50 → 40 (-10)
22% less capital invested
Capital invested by funds: $23.6M → $18.3M (-$5.27M)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
67% less call options, than puts
Call options by funds: $1K | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$240K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$132K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$104K |
| 4 |
E
Ergoteles
New York
|
+$43.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$43.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$632K |
| 2 |
State Street
Boston,
Massachusetts
|
-$601K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$482K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$428K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$389K |
CLLS Hedge Fund Activity: Q4 2022 in Review
40 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q4 2022, worth a combined $18.3M — down 22% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CLLS and 6 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, adding an estimated $240K. The largest seller was BlackRock, cutting an estimated $632K.
- 40 institutional investors held Cellectis (CLLS) as of Q4 2022, down from 50 in Q3 2022.
- Funds reported $18.3M of Cellectis stock for Q4 2022, down 22% quarter-over-quarter.
- 6 funds opened new Cellectis positions in Q4 2022 and 16 closed out, a net change of -10 holders.
- The largest Cellectis buyer in Q4 2022 was Millennium Management, an estimated $240K added.
- The largest Cellectis seller in Q4 2022 was BlackRock, an estimated $632K sold.
Based on aggregated 13F filings for Q4 2022.